speb/financial-data huggingface dataset:
Financial ratios for ENX.PA — quarterly report dated 2025-12-31
Total revenue: 542000000
Gross profit: 400470588.2352941
Operating income: 297176470.5882353
Net income: 184117647.05882353
Capital expenditures: 11554117.647058824
Operating cash flow: 100629411.76470588
Depreciation & amortization: 63743529.41176471
Net tangible assets: -2634325882.352941
Owner earnings: 236307058.82352942
Return on net tangible assets (%): -8.970304714633993
Capex to operating income (%): 3.8879651623119558
Buffett classification: The Great
Stock price: 147.38823529411766
P/E ratio: 24.210432116090733
Shares outstanding: 99740109
Book value: 5570501176.470581
P/B ratio: 2.638993905188807
Market cap (USD): 14700518653.552942
Debt to equity: 0.7183204130328551
Current ratio: 1.002712679929421
Quick ratio: 1.002712679929421
Effective tax rate (%): 26.629160806375996
COGS to revenue (%): 26.112437594964188
SG&A to revenue (%): 5.860646841762535
Free cash flow (dilution-adjusted): 46811764.705882356
Buyback yield (%): 0
Retained earnings: 2574845882.352941
Receivables turnover: 1.5873344014333213
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 3.034251364542243
FCF margin (%): 8.636856956804863
Revenue growth (%): 5.18264840182648
Rule of 40 score: 13.819505358631343
Financial ratios for ENX.PA — annual report dated 2025-12-31
Total revenue: 2138907058.8235295
Gross profit: 1733838823.5294118
Operating income: 1087344705.882353
Net income: 811891764.7058824
Capital expenditures: 29009411.76470588
Operating cash flow: 955383529.4117647
Depreciation & amortization: 235230588.23529413
Net tangible assets: -2634325882.352941
Owner earnings: 1018112941.1764706
Return on net tangible assets (%): -38.647949670794226
Capex to operating income (%): 2.6679130921197127
Buffett classification: The Great
Stock price: 147.38823529411766
P/E ratio: 18.106500512267644
Shares outstanding: 99740109
Book value: 5570501176.470581
P/B ratio: 2.638993905188807
Market cap (USD): 14700518653.552942
Debt to equity: 0.7183204130328551
Current ratio: 1.002712679929421
Quick ratio: 1.002712679929421
Effective tax rate (%): 26.688996465687854
Interest coverage ratio: 21.16086269661378
COGS to revenue (%): 18.938094276846172
SG&A to revenue (%): 5.091110303172979
Free cash flow (dilution-adjusted): 778082352.9411765
Buyback yield (%): 3.289159660328738
Retained earnings: 2574845882.352941
Receivables turnover: 6.264134236050098
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 11.102080696431576
FCF margin (%): 36.377567212721615
Revenue growth (%): 26.3340812701013
Rule of 40 score: 62.711648482822916
Financial ratios for EPP.L — annual report dated 2022-12-31
Total revenue: 0
Operating income: -743032.530120482
Net income: -1514690.3614457832
Capital expenditures: 215585.5421686747
Operating cash flow: -1024100
Net tangible assets: -510222.8915662651
Owner earnings: -1730275.903614458
Buffett classification: The Gruesome
Stock price: 0.00036144578313253013
Shares outstanding: 250825162
Book value: -127089.15662650601
Market cap (USD): 90659.69710843374
Debt to equity: 0
Current ratio: 0.35228718783266244
Quick ratio: 0.35228718783266244
Free cash flow (dilution-adjusted): -1301986.746987952
Buyback yield (%): 0
Retained earnings: -1514691.5662650603
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for EPP.L — annual report dated 2023-02-28
Total revenue: 0
Operating income: -737078.3132530121
Net income: -737078.3132530121
Capital expenditures: 0
Operating cash flow: -100746.98795180723
Net tangible assets: 599430.1204819278
Owner earnings: -737078.3132530121
Return on net tangible assets (%): -122.96317586784235
Buffett classification: The Gruesome
Stock price: 0.00036144578313253013
Shares outstanding: 250825162
Book value: 599430.1204819276
P/B ratio: 0.15124314579912249
Market cap (USD): 90659.69710843374
Debt to equity: 0
Current ratio: 3.146279911478847
Quick ratio: 3.146279911478847
Free cash flow (dilution-adjusted): -545796.3855421687
Buyback yield (%): 0
Retained earnings: -477414.4578313253
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -122.96317586784238
Rule of 40 score: 0
Financial ratios for EPP.L — annual report dated 2023-12-31
Total revenue: 0
Operating income: -753306.3291139241
Net income: -2355589.8734177216
Capital expenditures: 360307.59493670886
Operating cash flow: -472041.7721518987
Depreciation & amortization: 0
Net tangible assets: 1438163.2911392404
Owner earnings: -2715897.4683544305
Return on net tangible assets (%): -188.844861017349
Buffett classification: The Gruesome
Stock price: 0.0005063291139240507
Shares outstanding: 250825162
Book value: 2362126.5822784808
P/B ratio: 0.05376514661750837
Market cap (USD): 127000.08202531646
Debt to equity: 0
Current ratio: 1.95652507013036
Quick ratio: 1.95652507013036
Interest coverage ratio: -735.6143386897405
Free cash flow (dilution-adjusted): -1714121.5189873418
Buyback yield (%): 0
Retained earnings: -5494984.810126582
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -31.891022892909206
Rule of 40 score: 0
Financial ratios for EPP.L — quarterly report dated 2024-12-31
Capital expenditures: 0
Net tangible assets: 1583136.25
Buffett classification: The Gruesome
Stock price: 0.001125
Shares outstanding: 250825162
Book value: 1583136.25
P/B ratio: 0.17824006446065524
Market cap (USD): 282178.30724999995
Debt to equity: 0
Current ratio: 0.8742324309969628
Quick ratio: 0.8742324309969628
Buyback yield (%): 0
Retained earnings: -6848386.25
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for EPP.L — annual report dated 2024-12-31
Total revenue: 0
Operating income: -1340423.75
Net income: -1504588.75
Capital expenditures: 727076.25
Operating cash flow: -774665
Depreciation & amortization: 2577.5
Net tangible assets: 1583136.25
Owner earnings: -2229087.5
Return on net tangible assets (%): -140.80199982787332
Buffett classification: The Gruesome
Stock price: 0.001125
Shares outstanding: 250825162
Book value: 1583136.25
P/B ratio: 0.17824006446065524
Market cap (USD): 282178.30724999995
Debt to equity: 0
Current ratio: 0.8742324309969628
Quick ratio: 0.8742324309969628
Interest coverage ratio: -875.378775510204
Free cash flow (dilution-adjusted): -1755491.25
Buyback yield (%): 0
Retained earnings: -6848386.25
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -84.66888115283824
Rule of 40 score: 0
Financial ratios for EYE.L — annual report dated 2021-06-30
Total revenue: 31666666.666666668
Gross profit: 28702777.77777778
Operating income: 325000
Net income: -79166.66666666667
Capital expenditures: 306944.44444444444
Operating cash flow: 3337500
Depreciation & amortization: 4309722.222222222
Net tangible assets: -1572222.2222222222
Owner earnings: 3923611.1111111105
Capex to operating income (%): 94.44444444444444
Buffett classification: The Gruesome
Stock price: 0.0726388888888889
Shares outstanding: 30225571
Book value: 7493055.555555556
P/B ratio: 0.2930115594624653
Market cap (USD): 2195551.8934722226
Debt to equity: 0.29712696941612604
Current ratio: 0.8578364116094988
Quick ratio: 0.8578364116094988
Effective tax rate (%): 145.23809523809524
Interest coverage ratio: 2.1666666666666665
COGS to revenue (%): 9.359649122807017
Free cash flow (dilution-adjusted): -2112500
Buyback yield (%): 0
Retained earnings: -27283333.333333336
Receivables turnover: 4.889556079776968
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 3.700774948600347
FCF margin (%): -6.671052631578947
Rule of 40 score: -6.671052631578947
Financial ratios for EYE.L — annual report dated 2022-06-30
Total revenue: 38618292.68292683
Gross profit: 36134146.34146342
Operating income: 895121.9512195123
Net income: 675609.756097561
Capital expenditures: 217073.17073170733
Operating cash flow: 9032926.829268293
Depreciation & amortization: 4743902.439024391
Net tangible assets: 2321951.2195121953
Owner earnings: 5202439.024390244
Return on net tangible assets (%): 224.0546218487395
Capex to operating income (%): 24.250681198910083
Buffett classification: The Great
Stock price: 0.0628048780487805
P/E ratio: 2.8097778095667874
Shares outstanding: 30225571
Book value: 10447560.975609757
P/B ratio: 0.18169918366989612
Market cap (USD): 1898313.3006097565
Debt to equity: 0.060464573362904166
Current ratio: 1.165613459171112
Quick ratio: 1.165613459171112
Effective tax rate (%): 19.124087591240873
Interest coverage ratio: 14.680000000000001
COGS to revenue (%): 6.432563867748761
Free cash flow (dilution-adjusted): 530487.8048780491
Buyback yield (%): 0
Retained earnings: -22206097.56097561
Receivables turnover: 4.181013995246897
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 6.716076493732272
FCF margin (%): 1.3736697508447284
Revenue growth (%): 21.95250320924263
Rule of 40 score: 23.32617296008736
Financial ratios for EYE.L — annual report dated 2023-06-30
Total revenue: 54524050.63291139
Gross profit: 51877215.18987341
Operating income: -784810.1265822784
Net income: 1503797.4683544303
Capital expenditures: 216455.69620253163
Operating cash flow: 15496202.531645568
Depreciation & amortization: 7196202.531645569
Net tangible assets: 5800000
Owner earnings: 8483544.303797469
Return on net tangible assets (%): 146.2680052378874
Buffett classification: The Gruesome
Stock price: 0.06518987341772152
P/E ratio: 1.3102835913299664
Shares outstanding: 30225571
Book value: 30430379.746835444
P/B ratio: 0.06475111923876871
Market cap (USD): 1970401.1474683546
Debt to equity: 0.10794509151414308
Current ratio: 1.2132440315436968
Quick ratio: 1.2132440315436968
Interest coverage ratio: -3.6470588235294117
COGS to revenue (%): 4.854436551051679
Free cash flow (dilution-adjusted): 5317721.518987342
Buyback yield (%): 0
Retained earnings: -21198734.17721519
Receivables turnover: 5.710460029166114
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -2.1351332736414346
FCF margin (%): 9.752983238148303
Revenue growth (%): 41.18710809040117
Rule of 40 score: 50.94009132854947
Financial ratios for EYE.L — annual report dated 2024-06-30
Total revenue: 60421518.98734177
Gross profit: 44088607.594936706
Operating income: 1051898.7341772153
Net income: 5759493.670886076
Capital expenditures: 437974.68354430376
Operating cash flow: 12003797.46835443
Depreciation & amortization: 11263291.139240505
Net tangible assets: 19073417.721518986
Owner earnings: 16584810.126582276
Return on net tangible assets (%): 86.95248208123174
Capex to operating income (%): 41.63658243080625
Buffett classification: The Good
Stock price: 0.060759493670886074
P/E ratio: 0.3188631665934066
Shares outstanding: 30225571
Book value: 41610126.58227848
P/B ratio: 0.04413565977123387
Market cap (USD): 1836490.3898734176
Debt to equity: 0.03364565587734242
Current ratio: 1.539943094769096
Quick ratio: 1.539943094769096
Effective tax rate (%): -532.8233657858136
Interest coverage ratio: 5.431372549019609
COGS to revenue (%): 27.031613349255235
Free cash flow (dilution-adjusted): -517721.5189873418
Buyback yield (%): 0
Retained earnings: -12500000
Receivables turnover: 6.66848281642917
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 2.219610566521542
FCF margin (%): -0.8568495590053004
Revenue growth (%): 10.816269675442259
Rule of 40 score: 9.959420116436958
Financial ratios for EYE.L — quarterly report dated 2024-12-31
Capital expenditures: 0
Net tangible assets: 23841250
Buffett classification: The Gruesome
Stock price: 0.06012499999999999
Shares outstanding: 30225571
Book value: 44863750
P/B ratio: 0.04050736856314953
Market cap (USD): 1817312.4563749998
Debt to equity: 0
Current ratio: 1.8003685503685503
Quick ratio: 1.8003685503685503
Buyback yield (%): 0
Retained earnings: -8905000
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for EYE.L — annual report dated 2025-06-30
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 0.027671232876712328
Shares outstanding: 30225571
Market cap (USD): 836378.8139726027
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for FFU.V — quarterly report dated 2025-03-31
Total revenue: 0
Operating income: -173280.41958041958
Net income: -189197.90209790212
Capital expenditures: 16541.25874125874
Operating cash flow: -174945.45454545456
Net tangible assets: 6364916.783216784
Owner earnings: -205739.16083916085
Return on net tangible assets (%): -3.2323935700410167
Buffett classification: The Gruesome
Stock price: 0.04195804195804196
Shares outstanding: 82774874
Book value: 6364916.783216784
P/B ratio: 0.5456586086909326
Market cap (USD): 3473071.6363636367
Debt to equity: 0
Current ratio: 47.28068652330707
Quick ratio: 47.28068652330707
Free cash flow (dilution-adjusted): -228534.96503496505
Buyback yield (%): 0
Retained earnings: -1151405.5944055945
Receivables turnover: 0
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -2.722430245079259
Rule of 40 score: 0
Financial ratios for FFU.V — quarterly report dated 2025-06-30
Total revenue: 0
Operating income: -111765.69343065693
Net income: -71389.7810218978
Capital expenditures: 112548.17518248175
Operating cash flow: -241845.98540145982
Net tangible assets: 7354002.189781021
Owner earnings: -183937.95620437956
Return on net tangible assets (%): -2.5011952873766634
Buffett classification: The Gruesome
Stock price: 0.0656934306569343
Shares outstanding: 82774874
Book value: 7354002.189781021
P/B ratio: 0.7394294025111506
Market cap (USD): 5437765.445255473
Debt to equity: 0
Current ratio: 9.850529569137175
Quick ratio: 9.850529569137175
Free cash flow (dilution-adjusted): -388812.40875912405
Buyback yield (%): 0
Retained earnings: -1269916.7883211677
Receivables turnover: 0
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -1.5197941276923248
Rule of 40 score: 0
Financial ratios for FFU.V — quarterly report dated 2025-09-30
Total revenue: 0
Operating income: -269048.2014388489
Net income: -146092.8057553957
Capital expenditures: 790417.9856115108
Operating cash flow: 197554.6762589928
Net tangible assets: 7163715.82733813
Owner earnings: -936510.7913669065
Return on net tangible assets (%): -13.072975170134466
Buffett classification: The Gruesome
Stock price: 0.07194244604316548
Shares outstanding: 82774874
Book value: 7163715.82733813
P/B ratio: 0.831276260812759
Market cap (USD): 5955026.906474821
Debt to equity: 0
Current ratio: 4.248982862099255
Quick ratio: 4.248982862099255
Free cash flow (dilution-adjusted): -644255.3956834533
Buyback yield (%): 0
Retained earnings: -1397738.129496403
Receivables turnover: 0
Capitalized R&D asset: 66.18705035971223
ROCI (R&D-adjusted, %): -3.7550567032653026
Rule of 40 score: 0
Financial ratios for FFU.V — annual report dated 2025-09-30
Total revenue: 0
Operating income: -752337.4100719425
Net income: -888907.1942446043
Capital expenditures: 975305.7553956836
Operating cash flow: -686607.9136690648
Net tangible assets: 7163715.82733813
Owner earnings: -1864212.949640288
Return on net tangible assets (%): -26.022988551920072
Buffett classification: The Gruesome
Stock price: 0.07194244604316548
Shares outstanding: 82774874
Book value: 7163715.82733813
P/B ratio: 0.831276260812759
Market cap (USD): 5955026.906474821
Debt to equity: 0
Current ratio: 4.248982862099255
Quick ratio: 4.248982862099255
Free cash flow (dilution-adjusted): -1925958.9928057555
Buyback yield (%): 0
Retained earnings: -1397738.129496403
Receivables turnover: 0
Capitalized R&D asset: 771.9424460431655
ROCI (R&D-adjusted, %): -10.493740877684948
Rule of 40 score: 0
Financial ratios for FFU.V — quarterly report dated 2025-12-31
Total revenue: 0
Operating income: -155462.77372262772
Net income: -85874.45255474452
Capital expenditures: 17021.167883211678
Operating cash flow: -228317.51824817515
Net tangible assets: 7444705.839416058
Owner earnings: -102895.6204379562
Return on net tangible assets (%): -1.38213144558613
Buffett classification: The Gruesome
Stock price: 0.0437956204379562
Shares outstanding: 82774874
Book value: 7444705.839416058
P/B ratio: 0.48694697167349704
Market cap (USD): 3625176.9635036495
Debt to equity: 0
Current ratio: 39.63508020405108
Quick ratio: 39.63508020405108
Free cash flow (dilution-adjusted): -340299.27007299266
Buyback yield (%): 0
Retained earnings: -1504018.2481751824
Receivables turnover: 0
Capitalized R&D asset: 1555.2942288504962
ROCI (R&D-adjusted, %): -2.074564721066159
Rule of 40 score: 0
Financial ratios for FLNC — annual report dated 2022-09-30
Total revenue: 1198603000
Gross profit: -62354000
Operating income: -283521000
Net income: -104485000
Capital expenditures: 7934000
Operating cash flow: -282385000
Depreciation & amortization: 7108000
Net tangible assets: 359283000
Owner earnings: -105311000
Return on net tangible assets (%): -29.311434161928062
Buffett classification: The Gruesome
Stock price: 14.59
Shares outstanding: 132811490
Book value: 629208000
P/B ratio: 3.0796169773747315
Market cap (USD): 1937719639.1
Debt to equity: 0.0043594487037672755
Current ratio: 1.4435208745131654
Quick ratio: 0.8551866984297809
Interest coverage ratio: -140.49603567889
COGS to revenue (%): 105.20222292118409
R&D to revenue (%): 5.017674743013325
SG&A to revenue (%): 12.841366157101225
Free cash flow (dilution-adjusted): -334450000
Buyback yield (%): 0.2587061563936234
Retained earnings: -104544000
Inventory turnover: 1.9318054034179262
Receivables turnover: 3.354856496694414
Capitalized R&D asset: 60142000
ROCI (R&D-adjusted, %): -34.958322143763596
FCF margin (%): -27.903317445392677
Rule of 40 score: -27.903317445392677
Financial ratios for FLNC — annual report dated 2023-09-30
Total revenue: 2217978000
Gross profit: 140955000
Operating income: -112609000
Net income: -69620000
Capital expenditures: 2989000
Operating cash flow: -111927000
Depreciation & amortization: 10665000
Net tangible assets: 320574000
Owner earnings: -61944000
Return on net tangible assets (%): -19.32283965636639
Buffett classification: The Gruesome
Stock price: 22.99
Shares outstanding: 132811490
Book value: 556330000
P/B ratio: 5.488354313267306
Market cap (USD): 3053336155.1
Debt to equity: 0.09088670393471501
Current ratio: 1.6025469950902753
Quick ratio: 1.3009321905472042
COGS to revenue (%): 93.6448873703887
R&D to revenue (%): 2.989524693211565
SG&A to revenue (%): 7.999267801574226
Free cash flow (dilution-adjusted): -151071000
Buyback yield (%): 0.0911789550374227
Retained earnings: -174164000
Inventory turnover: 9.235194728394019
Receivables turnover: 5.923659351489075
Capitalized R&D asset: 106602140
ROCI (R&D-adjusted, %): -12.40402997961327
Rosenberg metric: 3.3804828572378702
FCF margin (%): -6.811203717980972
Revenue growth (%): 85.04692546239247
Rule of 40 score: 78.23572174441149
Financial ratios for FLNC — annual report dated 2024-09-30
Total revenue: 2698562000
Gross profit: 341080000
Operating income: 26621000
Net income: 30367000
Capital expenditures: 8115000
Operating cash flow: 79685000
Depreciation & amortization: 14482000
Net tangible assets: 384620000
Owner earnings: 36734000
Return on net tangible assets (%): 9.550725391295305
Capex to operating income (%): 30.483452913113705
Buffett classification: The Good
Stock price: 22.71
P/E ratio: 99.32324358349524
Shares outstanding: 132811490
Book value: 607139000
P/B ratio: 4.967806281428141
Market cap (USD): 3016148937.9
Debt to equity: 0.050005023561326155
Current ratio: 1.334919191156903
Quick ratio: 1.189863643765863
Effective tax rate (%): 23.263336113006343
COGS to revenue (%): 87.3606757969615
R&D to revenue (%): 2.4529731019706054
SG&A to revenue (%): 8.776452051129453
Free cash flow (dilution-adjusted): 36855000
Buyback yield (%): 0.05513653450939552
Retained earnings: -151448000
Inventory turnover: 12.910564564268542
Receivables turnover: 3.459379979514685
Capitalized R&D asset: 130467550
ROCI (R&D-adjusted, %): 3.696119640830595
Rosenberg metric: 3.018157962206102
FCF margin (%): 1.3657273762841098
Revenue growth (%): 21.667663069696815
Rule of 40 score: 23.033390445980924
Financial ratios for FLNC — quarterly report dated 2024-09-30
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 22.71
Shares outstanding: 132811490
Market cap (USD): 3016148937.9
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for FLNC — quarterly report dated 2024-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 15.88
Shares outstanding: 132811490
Market cap (USD): 2109046461.2
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for FLNC — quarterly report dated 2025-03-31
Total revenue: 431618000
Gross profit: 42582000
Operating income: -45081000
Net income: -31046000
Capital expenditures: 4353000
Operating cash flow: -46184000
Depreciation & amortization: 6189000
Net tangible assets: 302139000
Owner earnings: -29210000
Return on net tangible assets (%): -9.667735711046904
Buffett classification: The Gruesome
Stock price: 4.85
Shares outstanding: 132811490
Book value: 499063000
P/B ratio: 1.2906902064468815
Market cap (USD): 644135726.5
Debt to equity: 0.7812881339630467
Current ratio: 1.509741533851217
Quick ratio: 0.9907601473381911
COGS to revenue (%): 90.1343317470541
R&D to revenue (%): 5.124670426163877
SG&A to revenue (%): 14.503797339313932
Free cash flow (dilution-adjusted): -57584000
Buyback yield (%): 0.014593197696200134
Retained earnings: -223960000
Inventory turnover: 0.5571370673815692
Receivables turnover: 0.8328551112517584
Capitalized R&D asset: 22119000
ROCI (R&D-adjusted, %): -3.1938672694672183
FCF margin (%): -13.341426909906446
Rule of 40 score: -13.341426909906446
Financial ratios for FLNC — quarterly report dated 2025-06-30
Total revenue: 602533000
Gross profit: 89099000
Operating income: 4035000
Net income: 6894000
Capital expenditures: 3562000
Operating cash flow: -153865000
Depreciation & amortization: 8255000
Net tangible assets: 316446000
Owner earnings: 11587000
Return on net tangible assets (%): 3.661604191552429
Capex to operating income (%): 88.27757125154895
Buffett classification: The Gruesome
Stock price: 6.71
P/E ratio: 32.316691974905716
Shares outstanding: 132811490
Book value: 520844000
P/B ratio: 1.7110019466481325
Market cap (USD): 891165097.9
Debt to equity: 0.7494681708918601
Current ratio: 1.644416865066312
Quick ratio: 1.0627301450702948
Effective tax rate (%): 39.900618952140185
COGS to revenue (%): 85.21259416496689
R&D to revenue (%): 4.316941976622028
SG&A to revenue (%): 9.198666297115675
Free cash flow (dilution-adjusted): -167519000
Buyback yield (%): 0
Retained earnings: -217708000
Inventory turnover: 0.7847061214945416
Receivables turnover: 1.2331245152193
Capitalized R&D asset: 40830730
ROCI (R&D-adjusted, %): 1.4127743393419323
Rosenberg metric: 2.1030335910303357
FCF margin (%): -27.802460612115855
Revenue growth (%): 39.598672900574115
Rule of 40 score: 11.79621228845826
Financial ratios for FLNC — quarterly report dated 2025-09-30
Total revenue: 1041891000
Gross profit: 142903000
Operating income: 48427000
Net income: 24062000
Capital expenditures: 4860000
Operating cash flow: 265743000
Depreciation & amortization: 10414000
Net tangible assets: 337608000
Owner earnings: 29616000
Return on net tangible assets (%): 8.772303973839483
Capex to operating income (%): 10.035723873046027
Buffett classification: The Great
Stock price: 10.8
P/E ratio: 14.902793741168649
Shares outstanding: 132811490
Book value: 548848000
P/B ratio: 2.613408615864502
Market cap (USD): 1434364092
Debt to equity: 0.7120441360813923
Current ratio: 1.5063504793234523
Quick ratio: 1.1743121743121743
Effective tax rate (%): 47.81609195402299
COGS to revenue (%): 86.2842658205129
R&D to revenue (%): 2.0052001600935223
SG&A to revenue (%): 6.682272905707026
Free cash flow (dilution-adjusted): 251910000
Buyback yield (%): 0.018335651419807017
Retained earnings: -199762000
Inventory turnover: 1.9757326681537972
Receivables turnover: 1.4138205237111108
Capitalized R&D asset: 45618640
ROCI (R&D-adjusted, %): 4.486479323612714
Rosenberg metric: 2.068509476759832
FCF margin (%): 24.178152992971434
Revenue growth (%): 72.91849575044023
Rule of 40 score: 97.09664874341166
Financial ratios for FLNC — annual report dated 2025-09-30
Total revenue: 2262830000
Gross profit: 295785000
Operating income: -46337000
Net income: -48314000
Capital expenditures: 14884000
Operating cash flow: -145538000
Depreciation & amortization: 29343000
Net tangible assets: 337608000
Owner earnings: -33855000
Return on net tangible assets (%): -10.027902182412738
Buffett classification: The Gruesome
Stock price: 10.8
Shares outstanding: 132811490
Book value: 548848000
P/B ratio: 2.613408615864502
Market cap (USD): 1434364092
Debt to equity: 0.7120441360813923
Current ratio: 1.5063504793234523
Quick ratio: 1.1743121743121743
COGS to revenue (%): 86.92853639027236
R&D to revenue (%): 3.810140399411357
SG&A to revenue (%): 10.719187919552066
Free cash flow (dilution-adjusted): -194877000
Buyback yield (%): 0.05249713125138663
Retained earnings: -199762000
Inventory turnover: 4.323033306594288
Receivables turnover: 3.070604790394785
Capitalized R&D asset: 152448960
ROCI (R&D-adjusted, %): -2.8993867413252823
Rosenberg metric: -0.6842661832464688
FCF margin (%): -8.612091937971478
Revenue growth (%): -16.146821899960052
Rule of 40 score: -24.75891383793153
Financial ratios for FLNC — quarterly report dated 2025-12-31
Total revenue: 475234000
Gross profit: 23049000
Operating income: -63120000
Net income: -45070000
Capital expenditures: 5827000
Operating cash flow: -226792000
Depreciation & amortization: 8794000
Net tangible assets: 295575000
Owner earnings: -42103000
Return on net tangible assets (%): -14.24443880571767
Buffett classification: The Gruesome
Stock price: 19.78
Shares outstanding: 132811490
Book value: 488224000
P/B ratio: 5.380749967637805
Market cap (USD): 2627011272.2000003
Debt to equity: 0.801382152454611
Current ratio: 1.48317040122731
Quick ratio: 1.0795631254595879
COGS to revenue (%): 95.1499682261791
R&D to revenue (%): 3.90144644533009
SG&A to revenue (%): 13.441588775213894
Free cash flow (dilution-adjusted): -241428000
Buyback yield (%): 0.08964559935168442
Retained earnings: -244832000
Inventory turnover: 0.8363914486218135
Receivables turnover: 0.5924643231591847
Capitalized R&D asset: 41122270
ROCI (R&D-adjusted, %): -6.835833511958827
Rosenberg metric: -5.736837066819835
FCF margin (%): -50.80192073799433
Revenue growth (%): -54.38735913833597
Rule of 40 score: -105.18927987633029
Financial ratios for GAP — annual report dated 2022-01-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 15.01
Shares outstanding: 359978933
Market cap (USD): 5403283784.33
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for GAP — annual report dated 2023-01-31
Total revenue: 15616000000
Gross profit: 5359000000
Operating income: -69000000
Net income: -202000000
Capital expenditures: 227000000
Operating cash flow: 607000000
Depreciation & amortization: 540000000
Net tangible assets: 1945000000
Owner earnings: 111000000
Buffett classification: The Gruesome
Stock price: 11.96
Shares outstanding: 359978933
Book value: 2233000000
P/B ratio: 1.9280555479982089
Market cap (USD): 4305348038.68
Debt to equity: 2.695924764890282
Current ratio: 1.417997542997543
Quick ratio: 0.6842751842751843
Interest coverage ratio: -0.7840909090909091
COGS to revenue (%): 65.68263319672131
Free cash flow (dilution-adjusted): -115000000
Buyback yield (%): 2.8569118894673897
Retained earnings: 2140000000
Inventory turnover: 4.293428212641272
Receivables turnover: 31.86938775510204
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -0.8487084870848708
FCF margin (%): -0.7364241803278689
Rule of 40 score: -0.7364241803278689
Financial ratios for GAP — annual report dated 2024-01-31
Total revenue: 14889000000
Gross profit: 5775000000
Operating income: 560000000
Net income: 502000000
Capital expenditures: 344000000
Operating cash flow: 1532000000
Depreciation & amortization: 522000000
Net tangible assets: 2334000000
Owner earnings: 680000000
Return on net tangible assets (%): 29.13453299057412
Capex to operating income (%): 61.42857142857143
Buffett classification: The Good
Stock price: 17.37
P/E ratio: 12.455844753406375
Shares outstanding: 359978933
Book value: 2595000000
P/B ratio: 2.4095699677109828
Market cap (USD): 6252834066.21
Debt to equity: 2.0967244701348746
Current ratio: 1.4195736434108528
Quick ratio: 0.7751937984496124
Effective tax rate (%): 9.712230215827338
Interest coverage ratio: 6.222222222222222
COGS to revenue (%): 61.212976022567
Free cash flow (dilution-adjusted): 1032000000
Buyback yield (%): 0
Retained earnings: 2420000000
Inventory turnover: 4.568421052631579
Receivables turnover: 45.81230769230769
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 7.045797684952189
FCF margin (%): 6.93129155752569
Revenue growth (%): -4.6554815573770485
Rule of 40 score: 2.275810000148642
Financial ratios for GAP — quarterly report dated 2024-10-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 19.69
Shares outstanding: 359978933
Market cap (USD): 7087985190.77
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for GAP — annual report dated 2025-01-31
Total revenue: 15086000000
Gross profit: 6227000000
Operating income: 1112000000
Net income: 844000000
Capital expenditures: 440000000
Operating cash flow: 1486000000
Depreciation & amortization: 500000000
Net tangible assets: 2998000000
Owner earnings: 904000000
Return on net tangible assets (%): 30.153435623749164
Capex to operating income (%): 39.568345323741006
Buffett classification: The Good
Stock price: 22.96
P/E ratio: 9.79279182663507
Shares outstanding: 359978933
Book value: 3264000000
P/B ratio: 2.5322047492892157
Market cap (USD): 8265116301.68
Debt to equity: 1.677389705882353
Current ratio: 1.597972972972973
Quick ratio: 0.9631449631449631
Effective tax rate (%): 25.769569041336855
Interest coverage ratio: 12.781609195402298
COGS to revenue (%): 58.723319634097834
Free cash flow (dilution-adjusted): 913000000
Buyback yield (%): 0.9074282473769328
Retained earnings: 3039000000
Inventory turnover: 4.285921625544267
Receivables turnover: 45.99390243902439
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 12.886777146830456
FCF margin (%): 6.051968712713774
Revenue growth (%): 1.323124454295117
Rule of 40 score: 7.375093167008891
Financial ratios for GAP — quarterly report dated 2025-01-31
Total revenue: 4149000000
Gross profit: 1612000000
Operating income: 259000000
Net income: 206000000
Capital expenditures: 110000000
Operating cash flow: 616000000
Depreciation & amortization: 129000000
Net tangible assets: 2998000000
Owner earnings: 225000000
Return on net tangible assets (%): 7.5050033355570385
Capex to operating income (%): 42.471042471042466
Buffett classification: The Good
Stock price: 22.96
P/E ratio: 10.030480948640777
Shares outstanding: 359978933
Book value: 3264000000
P/B ratio: 2.5322047492892157
Market cap (USD): 8265116301.68
Debt to equity: 1.677389705882353
Current ratio: 1.597972972972973
Quick ratio: 0.9631449631449631
Effective tax rate (%): 24.264705882352942
Interest coverage ratio: 13.631578947368421
COGS to revenue (%): 61.1472644010605
Free cash flow (dilution-adjusted): 458000000
Buyback yield (%): 0
Retained earnings: 3039000000
Inventory turnover: 1.227382680212869
Receivables turnover: 12.649390243902438
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 3.0015065476880287
FCF margin (%): 11.03880453121234
Rule of 40 score: 11.03880453121234
Financial ratios for GAP — quarterly report dated 2025-04-30
Total revenue: 3463000000
Gross profit: 1448000000
Operating income: 260000000
Net income: 193000000
Capital expenditures: 83000000
Operating cash flow: -140000000
Depreciation & amortization: 121000000
Net tangible assets: 3321000000
Owner earnings: 231000000
Return on net tangible assets (%): 6.9557362240289065
Capex to operating income (%): 31.92307692307692
Buffett classification: The Good
Stock price: 21.09
P/E ratio: 9.834139503847151
Shares outstanding: 359978933
Book value: 3321000000
P/B ratio: 2.2860450758717255
Market cap (USD): 7591955696.97
Debt to equity: 1.6519120746763023
Current ratio: 1.7112824106517168
Quick ratio: 0.9765241765942537
Effective tax rate (%): 26.61596958174905
Interest coverage ratio: 11.304347826086957
COGS to revenue (%): 58.18654345942824
Free cash flow (dilution-adjusted): -260000000
Buyback yield (%): 0.9220285627843885
Retained earnings: 3171000000
Inventory turnover: 0.960896518836433
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 2.984731948111583
FCF margin (%): -7.507941091539127
Revenue growth (%): -16.53410460351892
Rule of 40 score: -24.042045695058047
Financial ratios for GAP — quarterly report dated 2025-07-31
Total revenue: 3725000000
Gross profit: 1536000000
Operating income: 292000000
Net income: 216000000
Capital expenditures: 98000000
Operating cash flow: 448000000
Depreciation & amortization: 122000000
Net tangible assets: 3433000000
Owner earnings: 240000000
Return on net tangible assets (%): 6.990969997087096
Capex to operating income (%): 33.56164383561644
Buffett classification: The Good
Stock price: 18.88
P/E ratio: 11.051060577300811
Shares outstanding: 359978933
Book value: 3433000000
P/B ratio: 1.9797268438799882
Market cap (USD): 6796402255.04
Debt to equity: 1.6288960093212934
Current ratio: 1.6818892711917424
Quick ratio: 0.9643415702220832
Effective tax rate (%): 27.027027027027028
Interest coverage ratio: 12.695652173913043
COGS to revenue (%): 58.765100671140935
Free cash flow (dilution-adjusted): 316000000
Buyback yield (%): 1.2065206990829798
Retained earnings: 3325000000
Inventory turnover: 0.9542284219703574
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 3.2629344060788914
FCF margin (%): 8.483221476510067
Revenue growth (%): 7.565694484550968
Rule of 40 score: 16.048915961061034
Financial ratios for GAP — quarterly report dated 2025-10-31
Total revenue: 3942000000
Gross profit: 1670000000
Operating income: 334000000
Net income: 236000000
Capital expenditures: 146000000
Operating cash flow: 299000000
Depreciation & amortization: 125000000
Net tangible assets: 3647000000
Owner earnings: 215000000
Return on net tangible assets (%): 5.895256375102824
Capex to operating income (%): 43.712574850299404
Buffett classification: The Good
Stock price: 22.34
P/E ratio: 9.449975749964748
Shares outstanding: 359978933
Book value: 3647000000
P/B ratio: 2.2050807137976416
Market cap (USD): 8041929363.22
Debt to equity: 1.5124760076775432
Current ratio: 1.7200365965233302
Quick ratio: 0.9701128392802684
Effective tax rate (%): 29.970326409495552
Interest coverage ratio: 14.521739130434783
COGS to revenue (%): 57.63571790969051
Free cash flow (dilution-adjusted): 116000000
Buyback yield (%): 0
Retained earnings: 3499000000
Inventory turnover: 0.9239528263521757
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 3.6739632603673966
FCF margin (%): 2.9426686960933535
Revenue growth (%): 5.825503355704698
Rule of 40 score: 8.768172051798052
Financial ratios for GAP — annual report dated 2026-01-31
Total revenue: 15366000000
Gross profit: 6268000000
Operating income: 1115000000
Net income: 816000000
Capital expenditures: 470000000
Operating cash flow: 1293000000
Depreciation & amortization: 496000000
Net tangible assets: 3535000000
Owner earnings: 842000000
Return on net tangible assets (%): 23.81895332390382
Capex to operating income (%): 42.152466367713004
Buffett classification: The Good
Stock price: 27.53
P/E ratio: 12.144877482218137
Shares outstanding: 359978933
Book value: 3801000000
P/B ratio: 2.6072665155196004
Market cap (USD): 9910220025.49
Debt to equity: 1.4761904761904763
Current ratio: 1.7506060606060605
Quick ratio: 1.0818181818181818
Effective tax rate (%): 27.915194346289752
Interest coverage ratio: 11.989247311827956
COGS to revenue (%): 59.208642457373415
Free cash flow (dilution-adjusted): 661000000
Buyback yield (%): 1.564041964772989
Retained earnings: 3608000000
Inventory turnover: 4.122338015405528
Receivables turnover: 48.62658227848101
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 11.948135447921132
FCF margin (%): 4.3017050631263825
Revenue growth (%): 1.8560254540633698
Rule of 40 score: 6.157730517189752
Financial ratios for GAP — quarterly report dated 2026-01-31
Total revenue: 4236000000
Gross profit: 1614000000
Operating income: 229000000
Net income: 171000000
Capital expenditures: 143000000
Operating cash flow: 686000000
Depreciation & amortization: 128000000
Net tangible assets: 3535000000
Owner earnings: 156000000
Return on net tangible assets (%): 4.413012729844413
Capex to operating income (%): 62.44541484716157
Buffett classification: The Good
Stock price: 27.53
P/E ratio: 12.144877482218137
Shares outstanding: 359978933
Book value: 3801000000
P/B ratio: 2.6072665155196004
Market cap (USD): 9910220025.49
Debt to equity: 1.4761904761904763
Current ratio: 1.7506060606060605
Quick ratio: 1.0818181818181818
Effective tax rate (%): 27.54237288135593
Interest coverage ratio: 9.541666666666666
COGS to revenue (%): 61.89801699716714
Free cash flow (dilution-adjusted): 489000000
Buyback yield (%): 0.030271779963348174
Retained earnings: 3608000000
Inventory turnover: 1.188038060715904
Receivables turnover: 13.405063291139241
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 2.4539219888555506
FCF margin (%): 11.543909348441925
Revenue growth (%): 7.4581430745814306
Rule of 40 score: 19.002052423023358
Financial ratios for GUFICBIO.NS — annual report dated 2022-03-31
Total revenue: 94029065.01384677
Gross profit: 38270552.55176052
Operating income: 17024897.797705393
Net income: 12638810.497164711
Capital expenditures: 11523763.681920085
Operating cash flow: 14010220.229460636
Depreciation & amortization: 2496241.5930370567
Net tangible assets: 35409178.42542529
Owner earnings: 3611288.408281684
Return on net tangible assets (%): 10.198735381244049
Capex to operating income (%): 67.6877113674847
Buffett classification: The Good
Stock price: 3.2791771066860083
P/E ratio: 26.018595495998024
Shares outstanding: 100282506
Book value: 35489647.89661084
P/B ratio: 9.265916044991416
Market cap (USD): 328844097.87630224
Debt to equity: 0.23925341300098843
Current ratio: 1.7207684912575856
Quick ratio: 1.100779714337216
Effective tax rate (%): 24.4391481122027
Interest coverage ratio: 32.22339257188498
COGS to revenue (%): 59.29923099190151
R&D to revenue (%): 0.6211025067375162
SG&A to revenue (%): 2.7726618406378254
Free cash flow (dilution-adjusted): 2477436.370829487
Buyback yield (%): 0
Retained earnings: 24865475.40551233
Inventory turnover: 3.658632359265499
Receivables turnover: 4.704775692184049
Capitalized R&D asset: 584016.8798628511
ROCI (R&D-adjusted, %): 38.904241478625266
FCF margin (%): 2.6347559347364125
Rule of 40 score: 2.6347559347364125
Financial ratios for GUFICBIO.NS — annual report dated 2023-03-31
Total revenue: 82795931.7904994
Gross profit: 41272923.26431182
Operating income: 14047612.667478686
Net income: 9708258.221680878
Capital expenditures: 22846419.00121803
Operating cash flow: -3238392.204628502
Depreciation & amortization: 2713897.6857490866
Net tangible assets: 42281291.10840439
Owner earnings: -10424263.093788065
Return on net tangible assets (%): -24.65455245219794
Capex to operating income (%): 162.6355989591688
Buffett classification: The Gruesome
Stock price: 2.2684531059683315
P/E ratio: 23.432232334112875
Shares outstanding: 100282506
Book value: 42363970.76735689
P/B ratio: 5.369802643364935
Market cap (USD): 227486162.20998785
Debt to equity: 0.9608537119021345
Current ratio: 1.6103279755037605
Quick ratio: 0.9737813901442539
Effective tax rate (%): 25.314722795628597
Interest coverage ratio: 17.380366803803668
COGS to revenue (%): 50.1510250905253
R&D to revenue (%): 0.7584943154485456
SG&A to revenue (%): 3.0682984712424157
Free cash flow (dilution-adjusted): -26088660.17052375
Buyback yield (%): 0
Retained earnings: 32556674.78684531
Inventory turnover: 1.8582172982843435
Receivables turnover: 3.3083604708717806
Capitalized R&D asset: 1019293.7455617035
ROCI (R&D-adjusted, %): 20.155822297994405
Rosenberg metric: 5.140897148822773
FCF margin (%): -31.509591843880123
Revenue growth (%): -11.946447858109797
Rule of 40 score: -43.45603970198992
Financial ratios for GUFICBIO.NS — annual report dated 2024-03-31
Total revenue: 92295982.73174241
Gross profit: 44413454.850701526
Operating income: 15899136.587120758
Net income: 10329248.111284327
Capital expenditures: 12966578.726466004
Operating cash flow: -894243.9141383859
Depreciation & amortization: 2040676.3400887398
Net tangible assets: 63189974.81712435
Owner earnings: -596654.275092937
Return on net tangible assets (%): -0.9442229986951111
Capex to operating income (%): 81.55523826979196
Buffett classification: The Gruesome
Stock price: 3.387116122840691
P/E ratio: 32.88414502701246
Shares outstanding: 100282506
Book value: 63863832.59383619
P/B ratio: 5.318636215770293
Market cap (USD): 339668492.9114683
Debt to equity: 0.6251227794776368
Current ratio: 1.6139792376754778
Quick ratio: 1.075119695287367
Effective tax rate (%): 25.534293235585253
Interest coverage ratio: 8.98373774401854
COGS to revenue (%): 51.87931962348904
R&D to revenue (%): 0.7032360682600881
SG&A to revenue (%): 2.6913445249970054
Free cash flow (dilution-adjusted): -14408394.29188152
Buyback yield (%): 0
Retained earnings: 42266039.093416475
Inventory turnover: 1.9916611009162415
Receivables turnover: 2.3327488753097954
Capitalized R&D asset: 1262545.8426353636
ROCI (R&D-adjusted, %): 18.169416104519904
Rosenberg metric: 5.000827076603402
FCF margin (%): -15.611074139336498
Revenue growth (%): 11.474055229284962
Rule of 40 score: -4.137018910051536
Financial ratios for GUFICBIO.NS — quarterly report dated 2024-09-30
Capital expenditures: 0
Net tangible assets: 67824820.83134258
Buffett classification: The Gruesome
Stock price: 4.621954132823698
Shares outstanding: 100282506
Book value: 68583385.09316769
P/B ratio: 6.758213267352875
Market cap (USD): 463501143.0566173
Debt to equity: 0.5154081445873865
Current ratio: 1.632733560106706
Quick ratio: 1.1053115781450693
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for GUFICBIO.NS — quarterly report dated 2024-12-31
Total revenue: 24221226.250145704
Gross profit: 13244935.307145353
Operating income: 3416015.85266348
Net income: 2250285.581070055
Capital expenditures: 0
Depreciation & amortization: 538314.4888681665
Owner earnings: 2788600.069938221
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 5.305746590511714
P/E ratio: 59.111782163717535
Shares outstanding: 100282506
Market cap (USD): 532073564.2974705
Effective tax rate (%): 26.48616743778679
Interest coverage ratio: 5.969729685685767
COGS to revenue (%): 45.31682595109866
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for GUFICBIO.NS — annual report dated 2025-03-31
Total revenue: 95838894.08463876
Gross profit: 52034697.21767594
Operating income: 13283656.768763151
Net income: 8142331.073182137
Capital expenditures: 8271989.7124152435
Operating cash flow: 14328735.094692541
Depreciation & amortization: 2462543.8391395835
Net tangible assets: 69526829.5534253
Owner earnings: 2332885.199906477
Return on net tangible assets (%): 3.3553740547220814
Capex to operating income (%): 62.27193201699575
Buffett classification: The Good
Stock price: 3.9235616758081453
P/E ratio: 48.32333563437736
Shares outstanding: 100282506
Book value: 70268505.96212298
P/B ratio: 5.599444472431086
Market cap (USD): 393464597.2956004
Debt to equity: 0.5593205394052806
Current ratio: 1.6114330994237753
Quick ratio: 1.0518537650700337
Effective tax rate (%): 26.018499438091254
Interest coverage ratio: 4.916509458453763
COGS to revenue (%): 45.706075059962366
R&D to revenue (%): 0.6843205202597347
SG&A to revenue (%): 3.200562474605269
Free cash flow (dilution-adjusted): 5487304.185176525
Buyback yield (%): 0
Retained earnings: 49216319.8503624
Inventory turnover: 1.7277762151344822
Receivables turnover: 2.6058102985026714
Capitalized R&D asset: 1297955.311392421
ROCI (R&D-adjusted, %): 14.343021679576584
Rosenberg metric: 11.741993551630419
FCF margin (%): 5.725550401625556
Revenue growth (%): 3.838640911591779
Rule of 40 score: 9.564191313217336
Financial ratios for GUFICBIO.NS — quarterly report dated 2025-03-31
Total revenue: 23967746.08370353
Gross profit: 13485211.596913723
Operating income: 2166249.707739069
Net income: 902443.3013794716
Capital expenditures: 0
Depreciation & amortization: 916927.7530979658
Net tangible assets: 69526829.5534253
Owner earnings: 1819371.0544774374
Return on net tangible assets (%): 2.6167899013422002
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 3.9235616758081453
P/E ratio: 108.99981103914003
Shares outstanding: 100282506
Book value: 70268505.96212298
P/B ratio: 5.599444472431086
Market cap (USD): 393464597.2956004
Debt to equity: 0.5593205394052806
Current ratio: 1.6114330994237753
Quick ratio: 1.0518537650700337
Effective tax rate (%): 26.654885082043535
Interest coverage ratio: 2.2060168099240456
COGS to revenue (%): 43.73600442102994
Buyback yield (%): 0
Retained earnings: 49216319.8503624
Inventory turnover: 0.413464349445979
Receivables turnover: 0.6516707039801098
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 2.370164484434447
Revenue growth (%): -1.0465207823268223
Rule of 40 score: -1.0465207823268223
Financial ratios for GUFICBIO.NS — quarterly report dated 2025-06-30
Total revenue: 26178621.577346127
Gross profit: 14386988.064591622
Operating income: 2993505.733676574
Net income: 1529417.2712380062
Capital expenditures: 0
Depreciation & amortization: 903217.8797098058
Owner earnings: 2432635.150947812
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 4.258717528668383
P/E ratio: 91.21348460783086
Shares outstanding: 100282506
Market cap (USD): 427074866.12099224
Effective tax rate (%): 24.33527651223508
Interest coverage ratio: 2.7705878530583954
COGS to revenue (%): 45.04298852372917
Buyback yield (%): 0
Capitalized R&D asset: 0
Revenue growth (%): 9.22437798665535
Rule of 40 score: 9.22437798665535
Financial ratios for GUFICBIO.NS — quarterly report dated 2025-09-30
Total revenue: 26725422.77339346
Gross profit: 14951071.025930101
Operating income: 3390428.4103720407
Net income: 1896730.5524239007
Capital expenditures: 0
Depreciation & amortization: 876324.6899661781
Net tangible assets: 70446843.2919955
Owner earnings: 2773055.242390079
Return on net tangible assets (%): 3.936379705327643
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 3.996054114994363
P/E ratio: 60.91227099467992
Shares outstanding: 100282506
Book value: 71157192.78466742
P/B ratio: 5.6316769265467
Market cap (USD): 400734320.7632469
Debt to equity: 0.584966545161062
Current ratio: 1.5483136216059468
Quick ratio: 1.0593368096149256
Effective tax rate (%): 25.577218292256713
Interest coverage ratio: 3.137680630184152
COGS to revenue (%): 44.056746444383045
Buyback yield (%): 0
Inventory turnover: 0.4547493117049991
Receivables turnover: 0.7316702413555443
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 3.752431904187218
Revenue growth (%): 2.088731809013622
Rule of 40 score: 2.088731809013622
Financial ratios for GUFICBIO.NS — quarterly report dated 2025-12-31
Total revenue: 25778088.448256657
Gross profit: 14524696.446474323
Operating income: 2816720.507964799
Net income: 1383936.7271917122
Capital expenditures: 0
Depreciation & amortization: 856856.4108276707
Owner earnings: 2240793.138019383
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 3.7428985184360033
P/E ratio: 65.70598040685651
Shares outstanding: 100282506
Market cap (USD): 375347243.1324496
Effective tax rate (%): 29.890181826390222
Interest coverage ratio: 3.026053135471517
COGS to revenue (%): 43.65487388396089
Buyback yield (%): 0
Capitalized R&D asset: 0
Revenue growth (%): -3.5446935046427903
Rule of 40 score: -3.5446935046427903